# US 2018/0021696 A1 · Affinity chromatography wash buffer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021696 A1
- Document ID: US20180021696A1
- Status: Published application
- Kind: A1
- Application number: 15/659,093
- Filed: 2017-07-25
- Published: 2018-01-25
- Earliest claimed: 2016-07-25
- Assignees: Cehpalon, Inc.
- Applicants: Cephalon, Inc.
- Inventors: Lu WANG; Tim ZHOU; Zhaoqing ZHANG; Mi JIN
- Web page: https://patentgrep.com/patent/US20180021696A1

## CPC

- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- B01D 15/426: {Specific type of solvent}
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- C07K 14/555: Interferons [IFN]
- C07K 16/18: against material from animals or humans
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A wash buffer comprising greater than 0 mM and less than about 500 mM arginine, greater than 0 mM and less than about 250 mM guanidine, greater than 0 mM and less than about 250 mM sodium chloride, and greater than 0 mM and less than about 50 mM of an anionic surfactant, or greater than 0% and less than about 0.25% w/v of a non-ionic surfactant. When used during affinity chromatography purification of a protein of interest, such as an antibody, the wash buffer significantly reduces the level of host cell proteins from the preparation. Following affinity chromatography with the wash buffer, the protein of interest may be further purified using membrane chromatography.

## Claims

### Claim 1

An affinity chromatography wash solution, comprising water, a basic amino acid, and guanidine.

### Claim 2 (depends on 1)

The wash solution according to claim 1, wherein the basic amino acid is arginine.

### Claim at position 3

3-14. (canceled)

### Claim 15 (depends on 1)

The wash solution of claim 1, wherein the solution further comprises an anionic surfactant.

### Claim at position 5

16-19. (canceled)

### Claim 20 (depends on 1)

The wash solution of claim 1, wherein the anionic surfactant comprises sodium octanoate.

### Claim 21 (depends on 1)

The wash solution of claim 1, wherein the solution further comprises sodium chloride.

### Claim at position 8

22-26. (canceled)

### Claim 27 (depends on 1)

The wash solution of claim 1, wherein the solution comprises a pH of about 7.5.

### Claim 28

A composition, comprising an aqueous carrier, a recombinantly-expressed or hybridoma-expressed antibody that specifically binds to:
(a) TNF-like ligand 1A (TL1a), and a level of host cell proteins from about 50 ppm to about 500 ppm of the composition,
(b) calcitonin gene-related peptide (CGRP), and a level of host cell proteins at a level of from about 400 ppm to about 800 ppm of the composition, or
(c) CD38, and a level of host cell proteins at a level of from about 50 ppm to about 500 ppm of the composition.

### Claim at position 11

29-33. (canceled)

### Claim 34 (depends on 28)

The composition of claim 28, wherein the antibody comprises:
(a) a VH comprising the amino acid sequence of SEQ ID NO: 5 and a VL comprising the amino acid sequence of SEQ ID NO: 7,
(b) a VH comprising the amino acid sequence of SEQ ID NO: 6 and a VL comprising the amino acid sequence of SEQ ID NO: 7,
(c) a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2, or
(d) a VH comprising the amino acid sequence of SEQ ID NO: 3 and a VL comprising the amino acid sequence of SEQ ID NO: 4.

### Claim 35

(canceled)

### Claim 36

A composition, comprising an aqueous carrier, a recombinantly-expressed or hybridoma-expressed antibody that specifically binds to calcitonin gene-related peptide (CGRP), and a level of host cell proteins at a level of from about 400 ppm to about 800 ppm of the composition.

### Claim at position 15

37-43. (canceled)

### Claim 44

A composition, comprising an aqueous carrier, a recombinantly-expressed or hybridoma-expressed antibody that specifically binds to CD38, and a level of host cell proteins at a level of from about 50 ppm to about 500 ppm of the composition.

### Claim at position 17

45-50. (canceled)

### Claim 51

A method of preparing a purified protein of interest, comprising loading a mixture comprising a protein of interest and one or more contaminant proteins onto an affinity chromatography ligand, washing the ligand with an aqueous wash solution comprising a basic amino acid and guanidine to elute the one or more contaminant proteins from the ligand, and then eluting the protein of interest from the ligand, thereby forming a purified eluate of the protein of interest.

### Claim 52 (depends on 51)

The method according to claim 51, wherein the affinity chromatography ligand comprises Protein A.

### Claim at position 20

53-86. (canceled)

### Claim 87 (depends on 51)

The method of claim 51, further comprising lowering the pH of the purified eluate of the protein of interest for a period of time sufficient to inactivate viruses.

### Claim 88

(canceled)

### Claim 89 (depends on 51)

The method of claim 51, further comprising filtering the purified eluate of the protein of interest to remove viruses.

### Claim 90

(canceled)

### Claim 91 (depends on 51)

The method of claim 51, further comprising loading the purified eluate of the protein of interest onto a membrane chromatography support and collecting flow through comprising a further-purified eluate from the membrane chromatography support.

### Claim at position 26

92-96. (canceled)

### Claim 97 (depends on 51)

The method of claim 51, further comprising formulating the purified eluate of the protein of interest as a composition including a pharmaceutically acceptable excipient.

### Claim 98 (depends on 91)

The method according to claim 91, further comprising formulating the further-purified eluate of the protein of interest as a composition including a pharmaceutically acceptable excipient.

### Claim 99 (depends on 51)

A host cell protein-reduced preparation of a protein of interest, produced by the method of claim 51.

### Claim at position 30

100-107. (canceled)

### Claim 108 (depends on 97)

A host cell protein-reduced composition of a protein of interest and a pharmaceutically acceptable excipient, produced by the method of claim 97.

### Claim 109 (depends on 98)

A host cell protein-reduced composition of a protein of interest and a pharmaceutically acceptable excipient, produced by the method of claim 98.

### Claim 110

(canceled)

### Claim 111 (depends on 1)

The wash solution of claim 1, wherein the solution comprises:
(a) 200 mM arginine, 0.05% w/v tributyl phosphate, and 150 mM NaCl,
(b) 250 mM arginine, 25 mM caprylic acid, and 150 mM sodium chloride,
(c) 100 mM arginine, 150 mM guanidine, 25 mM CA, and 150 mM sodium chloride,
(d) 0.1% w/v TRITON® X-100, 250 mM arginine, and 150 mM sodium chloride,
(e) 250 mM arginine and 0.1% w/v TRITON® X-100,
(f) 250 mM arginine and 0.05% w/v tributyl phosphate,
(g) about 50 mM to about 100 mM arginine, about 100 mM to 250 mM guanidine, 25 mM caprylic acid, or
(h) 350 mM guanidine and 0.05% w/v tributyl phosphate.

### Claim at position 35

112-118. (canceled)

### Claim 119 (depends on 52)

The method of claim 52, wherein the aqueous wash solution increases viral clearance from the mixture as measured by a virus log reduction value (LRV).

### Claim at position 37

120-124. (canceled)
